Inventor · disambiguated record
Jeffrey Carlson
Also filed as: CARLSON JEFFREY · CARLSON JEFFREY C
17 granted patents·7 pending applications·261 citations·filing 2011–2025
92Inventor score
Top patents by PatentIndex Score
24 records- 0198US8501930B2Peptide-based in vivo siRNA delivery systemROZEMA DAVID B·Filed 2011·Granted Aug 6, 2013·180 cites·18 claims
- 0295US8802773B2In vivo polynucleotide delivery conjugates having enzyme sensitive linkagesROZEMA DAVID B·Filed 2013·Granted Aug 12, 2014·12 cites·22 claims
- 0395US8426554B2In vivo polynucleotide delivery conjugates having enzyme sensitive linkagesROZEMA DAVID B·Filed 2011·Granted Apr 23, 2013·47 cites·14 claims
- 0486US11180529B2Alpha-v beta-6 integrin ligands and uses thereofARROWHEAD PHARMACEUTICALS INC·Filed 2019·Granted Nov 23, 2021·3 cites·18 claims
- 0586US10927373B2Compositions and methods for inhibiting gene expression of Hif2alphaARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Feb 23, 2021·2 cites·20 claims
- 0686US9976141B2Compositions and methods for inhibiting gene expression of Hif2alphaARROWHEAD MADISON INC·Filed 2016·Granted May 22, 2018·5 cites·32 claims
- 0785US9487556B2Polyconjugates for delivery of RNAi triggers to tumor cells in vivoARROWHEAD MADISON INC·Filed 2014·Granted Nov 8, 2016·6 cites·18 claims
- 0883US9107957B2Peptide-based in vivo siRNA delivery systemARROWHEAD MADISON INC·Filed 2013·Granted Aug 18, 2015·5 cites·14 claims
- 0980US12110492B2RNAi agents for inhibiting expression of complement component C3 (C3), pharmaceutical compositions thereof, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2023·Granted Oct 8, 2024·0 cites·14 claims
- 1074US11840688B2Compositions and methods for inhibiting gene expression of Hif2alphaARROWHEAD PHARMACEUTICALS INC·Filed 2021·Granted Dec 12, 2023·0 cites·20 claims
- 1171US2025340877A1RNAi Agents for Inhibiting Expression of Complement Component C3 (C3), Pharmaceutical Compositions Thereof, and Methods of UseARROWHEAD PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 1269US12173086B2Alpha-v beta-6 integrin ligands and uses thereofARROWHEAD PHARMACEUTICALS INC·Filed 2021·Granted Dec 24, 2024·0 cites·15 claims
- 1369US9481661B2Disubstituted maleic anhydrides with altered kinetics of ring closureBLOKHIN ANDREI V·Filed 2012·Granted Nov 1, 2016·1 cites·4 claims
- 1466US2025092072A1Trialkyne Linking Agents and Methods of UseARROWHEAD PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1565US11912997B2RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2023·Granted Feb 27, 2024·0 cites·30 claims
- 1665US2025333735A1RNAi Agents for Inhibiting Expression of Complement Component C3 (C3), Pharmaceutical Compositions Thereof, and Methods of UseARROWHEAD PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 1763US10005815B2Biologically cleavable tetrapeptide linking agentsARROWHEAD MADISON INC·Filed 2016·Granted Jun 26, 2018·0 cites·21 claims
- 1858US10059681B2Disubstituted maleic anhydrides with altered kinetics of ring closureARROWHEAD MADISON INC·Filed 2016·Granted Aug 28, 2018·0 cites·7 claims
- 1957US2019062748A1Polyconjugates for Delivery of RNAi triggers to Tumor Cells In VivoARROWHEAD PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2054US2018258138A1Biologically Cleavable Tetrapeptide Linking AgentsARROWHEAD PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2151US12221610B2RNAi agents for inhibiting expression of HIF-2 alpha (EPAS1), compositions thereof, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2020·Granted Feb 11, 2025·0 cites·20 claims
- 2251US2017022497A1Polyconjugates for Delivery of RNAi triggers to Tumor Cells In VivoARROWHEAD PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 2350US12065458B2Trialkyne linking agents and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2019·Granted Aug 20, 2024·0 cites·19 claims
- 2441US2021093725A1Integrin targeting ligands and uses thereofARROWHEAD PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →